Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg

Katia B.B. Pagnano, MD PhD, Eliana Cristina Martins Miranda, PhD, Marcia T Delamain, MD, Gislaine OLIVEIRA Duarte, MD, Erich Vinicius De Paula, MD PhD, Valquiria Povoa, Bruna Rocha Vergilio, Irene Lorand-Metze, MD PhD, Carmino Antônio De Souza, MD PhD

Blood (2016) 128 (22): 1911.

https://doi.org/10.1182/blood.V128.22.1911.1911

Published: 2016

Journal Articles

Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study

Marcia T Delamain, MD, Eliana Cristina Martins Miranda, PhD, Maria Gomes da Silva, MDPhD, Joana Desterro, MD, Merli Francesco, MD, Carlos Chiattone, MD PhD, Stefano Luminari, MD, Katia BB Pagnano, Carmino Antonio De Souza, MD PhD, Massimo Federico

Blood (2015) 126 (23): 5032.

https://doi.org/10.1182/blood.V126.23.5032.5032

Published: 2015

Journal Articles

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

Talita Silveira Da Rocha, MD, Sergio Costa Fortier, MD, Nelson Siqueira de Castro, MD, Marcia T Delamain, MD, José Salvador Oliveira, PhD, Guilherme Perini, MD, Valeria Buccheri, PhD, Rafael Dezen Gaiolla, MD, Laura Fogliato, PhD, Andressa Laranja, Maeva Pinto, MD, Carlos Chiattone, MD PhD

Blood (2015) 126 (23): 5107.

https://doi.org/10.1182/blood.V126.23.5107.5107

Published: 2015

Journal Articles

Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

Katia B.B. Pagnano, MD PhD, Paola Morelato Assunção, MD, Roberto Zullli, Marcia T Delamain, MD, Gislaine OLIVEIRA Duarte, Irene Lorand-Metze, MD PhD, Carmino A De Souza, Sr., MD PhD

Blood (2015) 126 (23): 4031.

https://doi.org/10.1182/blood.V126.23.4031.4031

Published: 2015

Journal Articles

VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma

Guilherme Rossi Assis de Mendonça, Angelo Borsarelli Carvalho Brito, Rodrigo de Andrade Natal, Marcia T Delamain, MD, Carmino Antonio De Souza, MD PhD, Gisele W. B. Colleoni, MD, José Vassallo, MD PhD, Carmen Silvia Passos Lima, MD PhD

Blood (2014) 124 (21): 3022.

https://doi.org/10.1182/blood.V124.21.3022.3022

Published: 2014

Journal Articles

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Marcia T Delamain, MD, Eliana C M Miranda, MD PhD, Merli Francesco, MD, Carlos S Chiattone, MD PhD, Anna Fedina, Stefano Luminari, MD, Carmino Antonio De Souza, MD PhD, Federico Massimo, MD

Blood (2014) 124 (21): 5400.

https://doi.org/10.1182/blood.V124.21.5400.5400

Published: 2014

Journal Articles

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Beatriz F Ribeiro, Eliana C M Miranda, MEd, Marcia T Delamain, MD, Gislaine Borba Oliveira, MD,, Maria Helena Almeida, RN, Vagner O Duarte, Irene L Metze, MD, PhD, Carmino A De Souza, Sr., MD, PhD, Rosana A Silveira, Katia B. Pagnano, MD, PhD

Blood (2013) 122 (21): 5189.

https://doi.org/10.1182/blood.V122.21.5189.5189

Published: 2013

Journal Articles

Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase

Muriel Silva Moura, Katia B. Pagnano, MD, PhD, Thais Benevides, Carmino A De Souza, Sr., MD, PhD, Irene Lorand-Metze, MD, PhD, Marcia T Delamain, MD, Gislaine O. Duarte, PhD, Fernando V Pericole, MD, Priscila Percout, Maria Dias, Bruno Duarte, Paula Campos, Paola Assunção, Luciene Oliveira, Pamela Paul, Eliana Fernandes

Blood (2013) 122 (21): 5200.

https://doi.org/10.1182/blood.V122.21.5200.5200

Published: 2013

Journal Articles

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

Katia B. Pagnano, MD, Beatriz F Ribeiro, Eliana C M Miranda, Marcia T Delamain, MD, Carmino Antonio De Souza, PhD, Gislaine O Duarte, MD, Bruna Vergilio, Dulcinéia Martins Albuquerque, BSc, MSc, PhD, Andrey dos Santos, PhD, Anderson Tavares, Irene Lorand-Metze, MD, PhD

Blood (2012) 120 (21): 3787.

https://doi.org/10.1182/blood.V120.21.3787.3787

Published: 2012

Journal Articles

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Katia B. Pagnano, MD, Irene Lorand-Metze, MD, PhD, Eliana C M Miranda, Vagner O Duarte, Marcia T Delamain, MD, Gislaine O Duarte, MD, Carmino Antonio De Souza, MD, PhD

Blood (2012) 120 (21): 1681.

https://doi.org/10.1182/blood.V120.21.1681.1681

Published: 2012

Journal Articles

Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.

Rosana A Silveira, MSc, Angela A Fachel, Yuri B Moreira, Marcia T Delamain, MD, Carmino Antonio De Souza, MD, PhD, Fernando Ferreira Costa, Ph.D., M.D., Sergio Verjovski-Almeida, MD, PhD, Katia B.B. Pagnano, MD, PhD

Blood (2009) 114 (22): 3260.

https://doi.org/10.1182/blood.V114.22.3260.3260

Published: 2009

Journal Articles

Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.

Katia BB Pagnano, MD, PhD, Marcia T Delamain, MD, Eliana C.M. Miranda, M.Ed, Vagner O Duarte, Brunna Eulálio Alves, MD, Carmino Antonio De Souza, MD, PhD, Irene Lorand-Metze, MD, PhD

Blood (2009) 114 (22): 3289.

https://doi.org/10.1182/blood.V114.22.3289.3289

Published: 2009

Journal Articles

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.

Rosana A. Silveira, Dulcineia M. Albuquerque, PhD, Angela M. Assis, Edson Ichihara, Carmino A. de Souza, MD,PhD, Fernando F. Costa, MD,PhD, Marcia T. Delamain, MD, Afonso C. Vigorito, MD,PhD, Irene Lorand-Metze, MD,PhD, Eliana Miranda, Katia B.B. Pagnano, MD,PhD

Blood (2006) 108 (11): 4817.

https://doi.org/10.1182/blood.V108.11.4817.4817

Published: 2006

NARROW

Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib 400 Mg

Clinical Characteristics and Outcome of 104 Patients with Gastric Diffuse B-Cell Non-Hodgkin Lymphoma (DLBCL) a Multicenter Study

The Oral Mtor Inhibitor Everolimus in Relapsed and Refractory Hodgkin Lymphoma- Compassionate Use in 8 Centers in Brazil

Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

VEGF 2578 c>a, a Functional Angiogenic Polymorphism, Is Associated with Aggressiveness and Clinical Outcome of Follicular Lymphoma

Clinical Characteristics and Outcome of 41 Patients with Upper GI Diffuse B-Cell Non-Hodgkin Lymphoma. Results of Brazilian-Italy Lymphoma Registry

Treatment Results With Dasatinib Or Nilotinib In Third Line Therapy Of Chronic Myeloid Leukemia After Failure Of Two Tyrosine Kinase Inhibitors

Evaluation Of Anemia After Long-Term Treatment With Imatinib In Chronic Myeloid Leukemia In Chronic Phase

Early Assessment of Molecular Response in Chronic Myeloid Leukemia Patients On Dasatinib After Imatinib Failure Identify Patients with Poor Cytogenetic and Molecular Responses

EUTOS Score Is Predictive of Event-Free Survival, but Not for Progression-Free and Overall Survival in Patients with Early Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib: A Single Institution Experience

Gene Expression Profile in Responsive and Non-Responsive Chronic Myeloid Leukemia Patients Treated with Dasatinib.

Impact of Imatinib Dose Escalation in Chronic Myeloid Leukemia Patients in Chronic Phase with Sub-Optimal Response or Failure with Imatinib 400 Mg.

Detection of BCR-ABL Point Mutations in Patients with Chronic Myeloid Leukemia (CML) Resistant to Imatinib.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only